News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
hey were educated about the 7- step hand-washing technique trainings
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
_256_384.jpg)
GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Subscribe To Our Newsletter & Stay Updated
